

Supplementary figure 1. Differentiation of PMA-treated THP-1 and U937 cells. THP-1 and U937 cells ($0.2*10^6$ cells, 1ml, 12 well plates) were treated for 2 days with PMA ranging from 0.5 to 25 ng/ml and *IL-1β* mRNA, TNFα secretion and CD11c and CD14 surface expression were analysed. (**A**) *IL-1β* mRNA was quantified by RT-qPCR. The graphs show the mean +/- SEM (reported to 25 ng/ml PMA) of three independent experiments. The mean value (*IL-1β* transcripts per 2,000 *EF1* transcripts) of the reference condition is indicated on top of the relevant bar. (**B**) TNFα was quantified by ELISA (R&D Systems) in the cell culture supernatant (mean +/- SD of biological duplicates from one experiment). (**C**) Cells were stained with FITC anti-CD11c (BD Biosciences), APC-Cy7 anti-CD14 (BioLegend), APC Annexin V (BioLegend) and propidium iodide (PI) (Sigma-Aldrich) and analyzed by flow cytometry. Cell debris were excluded, living cells (Annexin V- and PI-negative) were selected and CD11c- and CD14-positive populations were defined based on isotype control stainings. The graphs show the percentage of CD11c- or CD14-positive cells amongst living cells (mean +/- SD of biological duplicates from one experiment).



Supplementary figure 2. Cell viability and proliferation of PMA-treated U937 cells. (**A**) U937 cells ($0.2*10^6$ cells, 1ml, 12 well plates) were treated for 2 days with PMA ranging from 0.5 to 25 ng/ml. Cells were stained with APC Annexin V (BioLegend) and propidium iodide (PI) (Sigma-Aldrich) and analyzed by flow cytometry. Cell debris were excluded and the percentage of Annexin V- PI-, Annexin V- PI+, Annexin V+ PI- and Annexin V+ PI+ cells are shown (mean +/- SD of biological duplicates from one experiment). (**B**) U937 cells ($2.5*10^6$ cells, 3 ml, 35 mm cell culture dishes) were treated for 2 days with 5 ng/ml of PMA and counted every day using Trypan Blue stain.



Supplementary figure 3. Induction of *TDO2* and *IDO1* in freshly isolated monocytes. Cells were isolated from peripheral blood mononuclear cells and treated with either one single dose of cytokines for 2 or 5 days or differentiated for 5 days and subsequently treated with cytokines for 2 other days. *TDO2* and *IDO1* mRNA were quantified by RT-qPCR (expressed as mRNA transcripts per 2,000 *EF1* transcripts). In parallel, the metabolite kynurenine was quantified in the supernatants by HPLC. The positive controls are THP-1 cells treated for 48h with 5 ng/ml of PMA. (**A**) Monocytes were treated with PMA at the indicated concentrations (ng/ml) for 2 or 5 days (n = 1-3). (**B**) Monocytes were treated for 5 days with the indicated cytokines (n = 1-3). (**C**) Monocytes were differentiated for 5 days and subsequently treated with the indicated cytokines for 2 days (n = 1-3). TDO could not be induced in freshly isolated monocytes and the secreted kynurenine was produced by IDO1.